|
Blood cells express at least members of the
1,
2,
3, and
7 integrin families, but none are found on mature red cells. The primary cellular ligands for the leukocyte-specific
2 integrins are the intercellular adhesion molecules (ICAM); 5 have been described. Platelets are known to adhere through the
IIb
3 integrin to fibrinogen. Among the ICAMs, ICAM-4 is unique due to its expression on erythroid cells. This molecule was originally described as a member of the LandsteinerWiener (LW) blood group of antigens, but subsequent cloning and adhesion assays showed that it is a member of the ICAM family of adhesion proteins.1 Its physiologic function has remained unknown, but it shows an interesting relationship to the Rh antigens.2 Thus, Rhnull cells lack the ICAM-4 molecule and they may be part of a large membrane protein complex. Whereas the other ICAMs specifically bind to
2 integrins, ICAM-4 has recently been found to interact with several types of integrins expressed on blood and endothelial cells.
In this issue, Mankelow and colleagues (page 1503) have used mutational analysis to map the binding site on ICAM-4 for
V integrins and visualized the binding site using a structural model based on the structure of ICAM-2. Interestingly, the binding site is located in the first immunoglobulin (Ig) domain adjacent to but partially separated from those previously described for
L
2 and
M
2. The binding site for
L
2 is also confined to the first Ig domain of ICAM-4, whereas the binding site for
M
2 also involves domain 2.3 A relatively large binding site also seems to be the case for ICAM-4 binding to the platelet integrin
IIb
3.4 The
4
1 integrin is known to bind to leucine–aspartic acid–valine (LDV) sequences and the binding site on ICAM-4 is evidently different from those of the other integrins. Based on the mutational studies, Mankelow et al synthesized peptides that inhibited the ICAM-4/
V-integrin interaction. The active peptides are clearly different from those previously described to interfere with ICAM/
2,
4
1,5 and
IIb
3 interactions. The findings that red cells may specifically bind through ICAM-4 to integrins expressed on all major types of blood and endothelial cells indicate that it may be possible to develop reagents specific for the different ICAM-4 (red cell)/integrin interactions. Because of the pivotal role of red cells in human physiology and disease such reagents would be of great value.
University of Helsinki
References
- Bailly P, Tontti E, Hermand P, et al. The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins. Eur J Immunol. 1995;25: 3316-3320. [Medline] [Order article via Infotrieve]
- Gahmberg CG. Molecular characterization of the human red cell Rho(D) antigen. EMBO J. 1983;2: 223-227. [Medline] [Order article via Infotrieve]
- Hermand P, Huet M, Callebaut I, et al. Binding sites of leukocyte
2 integrins (LFA-1, Mac-1) on the human ICAM-4/LW blood group protein. J Biol Chem. 2000;275: 26002-26010. [Abstract/Free Full Text] - Hermand P, Gane P, Huet M, et al. Red cell ICAM-4 is a novel ligand for platelet-activated
IIb
3 integrin. J Biol Chem. 2003;278: 4892-4898. [Abstract/Free Full Text] - Spring FA, Parsons SF, Ortlepp S, et al. Intercellular adhesion molecule-4 binds
4
1 and
v-family integrins through novel integrin-binding mechanisms. Blood. 2001;98: 458-466. [Abstract/Free Full Text]
Related Articles in Blood Online :
- Identification of critical amino-acid residues on the erythroid intercellular adhesion molecule-4 (ICAM-4) mediating adhesion to
V integrins.
Tosti J. Mankelow, Frances A. Spring, Stephen F. Parsons, R. Leo Brady, Narla Mohandas, Joel A. Chasis, and David J. Anstee Blood 2004 103: 1503-1508.[Abstract] [Full Text]
Does video-assisted thoracoscopic lobectomy produce equal cancer clearance compared to open lobectomy for non-small cell carcinoma of the lung
Acute myocarditis supported by extracorporeal membrane oxygenation successfully bridged to transplantation: a giant cell myocarditis
Acellular porcine and kangaroo aortic valve scaffolds show more intense immune-mediated calcification than cross-linked Toronto SPV valves in the sheep model
How does definition of ‘complete resection’ conduct surgical management of non-small cell lung cancer
First experience with closed circuit/centrifugal pump extracorporeal circulation: cellular trauma, coagulatory, and inflammatory response
Elevated anti-cholesterol antibody levels in the sera of non-small cell lung cancer patients
Prognostic value of the histological subtype in completely resected non-small cell lung cancer
Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy
Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival
Pulmonary Langerhans' cell histiocytosis presented with recurrent pneumothorax
